Literature DB >> 19022821

Interleukin 21 as a target of intervention in autoimmune disease.

R Ettinger1, S Kuchen, P E Lipsky.   

Abstract

Interleukin 21 (IL21) belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor gamma chain (gamma(C)). The IL21R is widely distributed on lympho-haematopoietic cells and IL21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 memory T cells. One essential role of IL21 is the promotion of B-cell activation and differentiation or death during humoral immune responses. Increased IL21 production is characteristic of certain autoimmune diseases and is likely to contribute to autoantibody production as well as pathological features of autoimmune disease. The critical role of IL21 in promoting humoral immune responses makes it an important focus of potential therapeutic interventions in conditions characterised by overproduction of pathogenic autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022821     DOI: 10.1136/ard.2008.098400

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Evaluation of a DLA-79 allele associated with multiple immune-mediated diseases in dogs.

Authors:  Steven G Friedenberg; Greg Buhrman; Lhoucine Chdid; Natasha J Olby; Thierry Olivry; Julien Guillaumin; Theresa O'Toole; Robert Goggs; Lorna J Kennedy; Robert B Rose; Kathryn M Meurs
Journal:  Immunogenetics       Date:  2015-12-28       Impact factor: 2.846

2.  Loss of interleukin-21 receptor activation in hypoxic endothelial cells impairs perfusion recovery after hindlimb ischemia.

Authors:  Tao Wang; Alexis Cunningham; Ayotunde O Dokun; Surovi Hazarika; Kevin Houston; Lingdan Chen; R John Lye; Rosanne Spolski; Warren J Leonard; Brian H Annex
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

3.  Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.

Authors:  Christian M Capitini; Terry J Fry; Crystal L Mackall
Journal:  Am J Immunol       Date:  2009-01-01

4.  In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Authors:  Yulia Vugmeyster; Heath Guay; Pamela Szklut; Ming D Qian; Macy Jin; Angela Widom; Vikki Spaulding; Frann Bennett; Leslie Lowe; Tatyana Andreyeva; David Lowe; Steven Lane; George Thom; Viia Valge-Archer; Davinder Gill; Deborah Young; Laird Bloom
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

5.  Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21.

Authors:  Travis Hughes; Xana Kim-Howard; Jennifer A Kelly; Kenneth M Kaufman; Carl D Langefeld; Julie Ziegler; Elena Sanchez; Robert P Kimberly; Jeffrey C Edberg; Rosalind Ramsey-Goldman; Michelle Petri; John D Reveille; Javier Martín; Elizabeth E Brown; Luis M Vilá; Graciela S Alarcón; Judith A James; Gary S Gilkeson; Kathy L Moser; Patrick M Gaffney; Joan T Merrill; Timothy J Vyse; Marta E Alarcón-Riquelme; Swapan K Nath; John B Harley; Amr H Sawalha
Journal:  Arthritis Rheum       Date:  2011-06

Review 6.  Targeting interleukin-21 in rheumatoid arthritis.

Authors:  Feng-Lai Yuan; Wei Hu; Wei-Guo Lu; Xia Li; Jian-Ping Li; Rui-Sheng Xu; Cheng-Wan Li; Fei-Hu Chen; Cheng Jin
Journal:  Mol Biol Rep       Date:  2010-09-17       Impact factor: 2.316

Review 7.  B cells in autoimmunity.

Authors:  Thomas Dörner; Annett M Jacobi; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

8.  Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.

Authors:  Yongjing Guo; Andrew A Hill; Renee C Ramsey; Frederick W Immermann; Christopher Corcoran; Deborah Young; Edward R Lavallie; Mark Ryan; Theresa Bechard; Richard Pfeifer; Garvin Warner; Marcia Bologna; Laird Bloom; Margot O'Toole
Journal:  J Transl Med       Date:  2010-05-26       Impact factor: 5.531

9.  Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Authors:  Agnès Doreau; Alexandre Belot; Jérémy Bastid; Benjamin Riche; Marie-Claude Trescol-Biemont; Bruno Ranchin; Nicole Fabien; Pierre Cochat; Claire Pouteil-Noble; Pierre Trolliet; Isabelle Durieu; Jacques Tebib; Berhouz Kassai; Stéphane Ansieau; Alain Puisieux; Jean-François Eliaou; Nathalie Bonnefoy-Bérard
Journal:  Nat Immunol       Date:  2009-05-31       Impact factor: 25.606

Review 10.  Developments in the scientific understanding of rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.